References:
1. Kapatral V, Anderson I, Ivanova N, Reznik G, Los T, Lykidis A, et al.
Genome Sequence and Analysis of the Oral Bacterium
<i>Fusobacterium
nucleatum</i> Strain ATCC 25586. Journal of
Bacteriology. 2002;184(7):2005-18.
2. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M,
Strauss J, et al. Fusobacterium nucleatum infection is prevalent in
human colorectal carcinoma. Genome research. 2012;22(2):299-306.
3. Afra K, Laupland K, Leal J, Lloyd T, Gregson D. Incidence, risk
factors, and outcomes of Fusobacterium species bacteremia. BMC Infect
Dis. 2013;13:264.
4. Pett E, Saeed K, Dryden M. Fusobacterium species infections: clinical
spectrum and outcomes at a district general hospital. Infection.
2014;42(2):363-70.
5. Dorsher CW, Rosenblatt JE, Wilson WR, Ilstrup DM. Anaerobic
Bacteremia: Decreasing Rate Over a 15-Year Period. Reviews of Infectious
Diseases. 1991;13(4):633-6.
6. Anne-Marie B, Fran, xe, ois L, Patrick D, xe, et al. Fusobacterium
Bacteremia: Clinical Experience with 40 Cases. Clinical Infectious
Diseases. 1997;25:S181-S3.
7. Huggan PJ, Murdoch DR. Fusobacterial infections: Clinical spectrum
and incidence of invasive disease. Journal of Infection.
2008;57(4):283-9.
8. Goldberg EA, Venkat-Ramani T, Hewit M, Bonilla HF. Epidemiology and
clinical outcomes of patients with Fusobacterium bacteraemia.
Epidemiology and Infection. 2013;141(2):325-9.
9. Rickard AH, Gilbert P, High NJ, Kolenbrander PE, Handley PS.
Bacterial coaggregation: an integral process in the development of
multi-species biofilms. Trends Microbiol. 2003;11(2):94-100.
10. Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont,
opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156-66.
11. de Andrade KQ, Almeida-da-Silva CLC, Coutinho-Silva R. Immunological
Pathways Triggered by Porphyromonas gingivalis and Fusobacterium
nucleatum: Therapeutic Possibilities? Mediators Inflamm.
2019;2019:7241312.
12. Garlet GP, Cardoso CR, Mariano FS, Claudino M, De Assis GF,
Campanelli AP, et al. Regulatory T cells attenuate experimental
periodontitis progression in mice. Journal of clinical periodontology.
2010;37(7):591-600.
13. Liu H, Redline RW, Han YW. <em>Fusobacterium
nucleatum</em> Induces Fetal Death in Mice via
Stimulation of TLR4-Mediated Placental Inflammatory Response. The
Journal of Immunology. 2007;179(4):2501-8.
14. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens
DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
administered in a prime-boost regimen in young and old adults (COV002):
a single-blind, randomised, controlled, phase 2/3 trial. The Lancet.
2020;396(10267):1979-93.
15. Miyagami T, Uehara Y, Harada T, Watari T, Shimizu T, Nakamura A, et
al. Delayed treatment of bacteremia during the COVID-19 pandemic.
Diagnosis. 2021(000010151520200114).
16. Wolff L, Martiny D, Deyi VYM, Maillart E, Clevenbergh P, Dauby N.
COVID-19-Associated Fusobacterium nucleatum Bacteremia, Belgium. Emerg
Infect Dis. 2021;27(3):975-7.